section name header

Pronunciation

PRAM-lin-tide

Classifications

Therapeutic Classification: antidiabetics

Pharmacologic Classification: hormones

Indications

High Alert


Action

  • Acts as a synthetic analogue of amylin, an endogenous pancreatic hormone that helps to control postprandial hyperglycemia; effects include slowed gastric emptying, suppression of glucagon secretion and regulation of food intake.
Therapeutic effects:
  • Improved control of postprandial hyperglycemia.

Pharmacokinetics

Absorption: 30–40% absorbed following SUBQ administration.

Distribution: Does not appear to significantly cross the placenta.

Metabolism/Excretion: Metabolized by the kidneys; major metabolite has pharmacologic properties similar to the parent compound.

Half-Life: 48 min.

Time/Action Profile

(effect on blood sugar*)

ROUTEONSETPEAKDURATION
SUBQrapid20 min3 hr



*Blood level.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Noted for concurrent use with insulin

Derm: local allergy

Endo: HYPOGLYCEMIA

GI: nausea, abdominal pain, anorexia, vomiting

MS: arthralgia

Neuro: dizziness, fatigue, headache

Resp: cough

Misc: injection site reactions, systemic allergic reactions

Interactions

Drug-drug:

Route/Dosage

Insulin-using Type 2 Diabetes

Type 1 Diabetes

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Symlin